Related Experiment Video
Updated: Mar 8, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
The Use of MitraClip for Symptomatic Patients with Hypertrophic Obstructive Cardiomyopathy
Felix Thomas1, Florian Rader, Robert J Siegel
1Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Insights
The MitraClip device offers a safe and effective treatment for hypertrophic obstructive cardiomyopathy (HOCM), reducing left-ventricular outflow tract gradients and improving symptoms without causing conduction abnormalities.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- Symptomatic hypertrophic obstructive cardiomyopathy (HOCM) presents treatment challenges.
- Current therapies like septal myectomy and alcohol septal ablation (ASA) carry risks of cardiac conduction abnormalities.
- The MitraClip system presents a novel, lower-risk alternative.
Purpose of the Study:
- To review published data on the use of the MitraClip system for symptomatic HOCM patients.
- To evaluate the safety and efficacy of MitraClip in treating HOCM with systolic anterior motion (SAM).
Main Methods:
- A review of 4 studies involving 15 symptomatic HOCM patients treated with MitraClip.
- Consolidation of data on mitral regurgitation (MR), left-ventricular outflow tract (LVOT) gradient, and NYHA class.
Main Results:
- MitraClip resolved SAM in all patients.
- Significant reduction in MR and LVOT gradient (mean 75.8 to 11.0 mm Hg).
- Symptomatic improvement and no associated conduction abnormalities or arrhythmias.
Conclusions:
- MitraClip therapy is a potentially safe and effective option for symptomatic HOCM.
- It may help high-risk patients avoid risks associated with traditional therapies.
Objectives:
Current nonpharmacological therapies for symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM), including septal myectomy and alcohol septal ablation (ASA), carry significant risks for serious cardiac conduction abnormalities. We present a review of the currently available published data regarding the novel use of the relatively low-risk MitraClip® system in the treatment of symptomatic patients.
Methods:
Data were collected from 4 separate studies on the use of the MitraClip on 15 symptomatic HOCM patients with systolic anterior motion (SAM) of the mitral valve apparatus. Information regarding the degree of mitral regurgitation (MR), left-ventricular outflow tract (LVOT) gradient, and NYHA class was consolidated.
Results:
After MitraClip treatment, all patients had a resolution of SAM, a reduction in MR, and a reduction in the LVOT gradient from a mean of 75.8 ± 39.7 to 11.0 ± 5.6 mm Hg. Nearly all patients demonstrated improvements in symptoms by either new NYHA class designations or improved exercise tolerance. The procedure was not associated with conduction abnormalities or arrhythmias.
Conclusion:
MitraClip therapy may be a safe and effective treatment for symptomatic HOCM patients; it can help to avoid the potential risks associated with alternative therapies in high-risk surgical patients.
More Related Videos
07:13A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
Published on: April 30, 2020
08:42Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Mitral Stenosis III: Medical Management
Mitral Regurgitation III: Medical Management
Mitral Valve Prolapse II: Assessment and Management
Mitral Stenosis I: Introduction